ELOX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 02:09):

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases...

Stats
今日成交量	1 650.00
平均成交量	8 270.00
市值	2.83M
EPS	$0 ( 2024-04-01 )
下一个收益日期	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0.0300 (3.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-24	Walts Alan Edmund	Buy	7 500	Restricted Stock Units
2024-01-24	Rubin Steven D	Buy	7 500	Restricted Stock Units
2024-01-24	Androski Lindsay	Buy	7 500	Restricted Stock Units
2024-01-24	Aggarwal Sumit	Buy	60 000	Restricted Stock Units
2023-01-30	Walts Alan Edmund	Buy	2 859	Stock Options (Right to Buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 28 846 630 \| Sell: 836 099

Eloxx Pharmaceuticals Inc 相关性

10 最正相关
PAIC	0.954
SVAC	0.941
MTSL	0.873
CASI	0.869
TLGT	0.866
AGMH	0.861
BLKB	0.857
SVOK	0.855
KC	0.851
ACACU	0.849

10 最负相关
NETE	-0.961
MMAC	-0.934
RAVN	-0.907
AMRB	-0.891
BOCH	-0.89
SHSP	-0.867
SRAC	-0.837
RMRM	-0.834
LWAC	-0.819
DFFN	-0.806

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Eloxx Pharmaceuticals Inc 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-16.65

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-16.65

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1 526.00

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1 378.77

Financial Reports:

No articles found.

Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.